DrugDashboards

clindamycin and benzoyl peroxide

clindamycin and benzoyl peroxide · CLINDAMYCIN PHOSPHATE 10 mg/g; BENZOYL PEROXIDE 50 mg/g · Gel · Topical · Glenmark Pharmaceuticals Inc., USA

NDC 68462-0486-27 · 1 JAR in 1 CARTON / 50 g in 1 JAR · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 21% over the past year, to $0.4661 per gram. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.4661per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D point of sale (median)$1.03per unitnegotiated price across 2,318 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$1.03per unit
middle half $0.9401$1.15 · 2,318 plans · Apr 1, 2026
Est. net of rebates
≈ $1.03
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
42%of plans cover it
tier 4 · prior auth 0% · step therapy 1% · qty limit 40%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00Jun 2019Sep 2026$0.4661
88 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$80.00
Reported to Texas DSHS · 2026 annual filing · Glenmark Pharmaceuticals Inc., USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$572,600
14,090 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

28Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 2 active manufacturers+20
  • price down 25% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for clindamycin and benzoyl peroxide (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA209252
TE code
AB
Approval date
Mar 14, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of clindamycin and benzoyl peroxide (Gel)

LabelerStrengthFirst seenLast seen
Glenmark Pharmaceuticals Inc., USACLINDAMYCIN PHOSPHATE 10 mg/g; BENZOYL PEROXIDE 50 mg/gAug 26, 2026Sep 3, 2026
NorthStar RxLLCCLINDAMYCIN PHOSPHATE 10 mg/g; BENZOYL PEROXIDE 50 mg/gAug 26, 2026Sep 2, 2026
Glenmark Pharmaceuticals Inc., USACLINDAMYCIN PHOSPHATE 50 mg/g; BENZOYL PEROXIDE 10 mg/gJul 22, 2026Aug 22, 2026
NorthStar RxLLCCLINDAMYCIN PHOSPHATE 50 mg/g; BENZOYL PEROXIDE 10 mg/gJul 22, 2026Aug 19, 2026
Glenmark Pharmaceuticals Inc., USABENZOYL PEROXIDE 50 mg/g; CLINDAMYCIN PHOSPHATE 10 mg/gJul 15, 2026Jul 19, 2026
NorthStar RxLLCBENZOYL PEROXIDE 50 mg/g; CLINDAMYCIN PHOSPHATE 10 mg/gJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "clindamycin and benzoyl peroxide — NDC 68462-0486-27," retrieved September 3, 2026, https://drugdashboards.com/drug/68462048627.

Free to cite with attribution — see how the data is put together.